HealthDay News — After approval, tirzepatide dispensations increased markedly among adults with type 2 diabetes prescribed glucose-lowering medications (GLMs) and among adults without diabetes ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years in adults with overweight or obesity who do not have diabetes ...

Each participant received weekly doses of tirzepatide—either 5 mg, 10 mg, or 15 mg—for three years. At the end of this period, the results were impressive. On average, participants lost ...